Department of Pulmonary Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Curr Opin Pulm Med. 2018 Jul;24(4):343-349. doi: 10.1097/MCP.0000000000000486.
The current review describes the latest evidence regarding the use of stents for malignant airway obstruction.
Therapeutic bronchoscopy, including stenting, can restore patency in up to 93% of patients with malignant central airway obstruction. The patients that benefit the most are those with worse baseline dyspnea, higher American Society of Anesthesiology score, poorer functional status, and central obstruction (rather than lobar). Early complications are relatively rare with stent placement, whereas late complications are not. Stents are a risk factor for lower respiratory tract infection, which, in turn, is a negative prognostic factor in terms of survival. Recent research has seen the development of personalized stents via three-dimensional printing, mini stents for more distal airways, and stents with drug-eluting and biodegradable properties.
Airway stents must be judiciously used, but we now have data that help guide patient selection and that inform us of what potential complications may occur and when. Stents are under development with newer properties that may extend the therapeutic reach of these interventions.
本文描述了恶性气道阻塞应用支架的最新证据。
治疗性支气管镜检查(包括支架置入术)可使 93%的恶性中央气道阻塞患者气道再通。获益最大的患者是那些基线呼吸困难更严重、美国麻醉医师协会评分更高、功能状态更差以及中央气道阻塞(而非肺叶)的患者。支架置入术的早期并发症相对较少,而晚期并发症则不少。支架是下呼吸道感染的一个危险因素,而后者在生存方面是一个负面的预后因素。最近的研究通过三维打印技术开发了个体化支架、用于更远端气道的迷你支架以及具有药物洗脱和生物可降解特性的支架。
气道支架必须谨慎使用,但我们现在有数据可以帮助指导患者选择,并告知我们可能发生哪些潜在并发症以及何时发生。具有新特性的支架正在开发中,这可能会扩大这些干预措施的治疗范围。